Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Update

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 106,800 shares, agrowthof335.9% from the July 15th total of 24,500 shares. Based on an average trading volume of 516,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately4.7% of the shares of the stock are short sold. Approximately4.7% of the shares of the stock are short sold. Based on an average trading volume of 516,000 shares, the days-to-cover ratio is currently 0.2 days.

Redhill Biopharma Stock Down 3.5%

Shares of RDHL stock opened at $1.36 on Friday. The stock has a 50-day simple moving average of $1.78 and a 200 day simple moving average of $2.57. Redhill Biopharma has a fifty-two week low of $1.06 and a fifty-two week high of $12.50.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen began coverage on Redhill Biopharma in a research note on Friday, May 16th. They set a “hold” rating for the company.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.